More on ZLAB
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $24.03 |
|
|||
| Open | $24.03 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $24.03 | ||||
| Day Low | $24.03 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 45,205 | ||||
- Zai Lab stock jumps on cancer drug data and $250m raise
- Zai Lab's zoci shows 81.8% response rate in lung cancer trial
- Zai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Can
- Form 8-K Zai Lab Ltd For: Oct 22
- Zai Lab raises $250M in PIPE financing for ADC drug development
- Zai Lab Announces $250 Million Private Placement
- Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026
- Zai Lab to share first ZL-1503 clinical data at ACAAI 2026
- Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases
- Zai Lab (ZLAB) Reiterated at Overweight by Cantor Fitzgerald
Entities mentioned with ZLAB
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- JPMorgan | View Related Stories »
- Citi | View Related Stories »
- PDUFA | View Related Stories »
- Jefferies & Co | View Related Stories »
- Goldman Sachs | View Related Stories »
- Show More...
